Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233939 | 0.91 | L3MBTL1 (0.45) | DHFRL3MBTL1TDP1TSHRTLR8 | |
| SCHEMBL2238461 | 0.87 | L3MBTL1 (0.42) | L3MBTL1TDP1TSHRCYP2D6STAT3 | |
| SCHEMBL2235660 | 0.87 | L3MBTL1 (0.39) | L3MBTL1TDP1TSHRSTAT3HTT | |
| SCHEMBL2236745 | 0.84 | DHFR (0.51) | DHFRL3MBTL1TSHRTLR8TLR7 | |
| SCHEMBL2234948 | 0.84 | DHFR (0.51) | DHFRL3MBTL1TSHRTLR8TLR7 | |
| SCHEMBL2233543 | 0.84 | TSHR (0.40) | DHFRL3MBTL1TDP1TSHRNUDT1 | |
| SCHEMBL2297897 | 0.83 | L3MBTL1 (0.37) | L3MBTL1TDP1TSHRCYP2D6STAT3 | |
| SCHEMBL12352386 | 0.83 | DHFR (0.36) | DHFRTLR8TLR7 | |
| SCHEMBL2238610 | 0.83 | DHFR (0.49) | DHFRL3MBTL1TSHRTLR8TLR7 | |
| SCHEMBL2237807 | 0.80 | TDP1 (0.41) | L3MBTL1TDP1TSHRSTAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536690-B1 | MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR USE | UNIV ARIZONA (US) | 2018-08-08 | — | — | EP | disclosed |
| US-8952025-B2 | Multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952025-B2 | Multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130267546-A1 | Multifunctional Radical Quenchers and Their Uses | Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Ari (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267546-A1 | Multifunctional Radical Quenchers and Their Uses | Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Ari (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2536690-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR USE | Arizona Board Of Regents (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103536-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR USE | ARIZONA BOARD OF REGENTS (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267546-A1 | Multifunctional Radical Quenchers and Their Uses | SQOR, GSR, GPX4 | DHFR 419/4885L3MBTL1 2443/4885TDP1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.